Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.66 |
| ▸ | ELANE | P08246 | 7/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.52 |
| ▸ | ESRRG | P62508 | 2/20 | 0.52 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073334 | 0.84 | ESRRB (0.60) | ESR1ESR2ESRRG | |
| SCHEMBL20836458 | 0.83 | ESRRB (0.60) | ESR1ESR2ELANEESRRG | |
| SCHEMBL5011583 | 0.82 | ESR1 (0.62) | ESR1ESR2PTGS2HSD17B3 | |
| SCHEMBL639545 | 0.82 | ESR1 (0.67) | ESR1ESR2ELANEESRRG | |
| SCHEMBL21956602 | 0.82 | ESR1 (0.67) | ESR1ESR2ELANEESRRG | |
| SCHEMBL639544 | 0.82 | ESR1 (0.67) | ESR1ESR2ELANEESRRG | |
| SCHEMBL5082218 | 0.81 | PSMB1 (0.64) | ESR1ESRRG | |
| SCHEMBL31061702 | 0.81 | ESR1 (1.00) | ESR1ESR2PTGS2ESRRGHSD17B3 | |
| SCHEMBL3827799 | 0.79 | ESR1 (0.70) | ESR1ESR2PTGS2ESRRG | |
| SCHEMBL14088321 | 0.79 | ESR1 (0.81) | ESR1ESR2PTGS2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| EP-1951250-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062151-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SHBG, ESR1, GPER1 | ESR1 2/4885ESR2 4/4885ELANE 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.